Nonalcoholic fatty liver disease
Conditions
Interventions
In Part 1, a single oral dose of MK-7480 30, 90, 240, 300 mg or placebo will be administered. In Part 2, multiple oral doses of MK-7480 120 or 240 mg, or placebo will be administered once daily for 14
Sponsors
Yoshitsugu Hiroyuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Healthy Japanese males or females aged 18 to 55 years old
Exclusion criteria
Exclusion criteria: Has a history of clinically significant abnormalities or diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics | — |
Contacts
Public ContactMSDJRCT inquiry mailbox
MSD K.K.
Outcome results
None listed